$WHG

Westwood Holdings CEO Brian Casey on Y'all Street and an ETF tracking the AI power ecosystem

Westwood Holdings Group CEO Brian Casey highlights Dallas's growth as a financial hub, citing lower taxes, business-friendly policies, and the new Texas Stock Exchange (TXSE). Energy Transfer, Sunoco, and Dillard's are moving listings to TXSE. Westwood launched the TXSE's first ETF, focusing on AI power infrastructure, expecting a $600B investment over 10 years.

Original reporting
Published Sep 26, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 26, 2026, 4:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Westwood Holdings CEO Brian Casey on Y'all Street and an ETF tracking the AI power ecosystem — source image
Decision brief

The 30-second read

$WHGBullishMed
01

Why it matters

The ETF could generate new fee revenue for Westwood and signal a shift of financial services to Texas, influencing regional capital flows.

02

Market read

New ETF launch on a nascent exchange could affect Westwood's stock and broader Texas financial ecosystem.

03

What to watch

Potential competition from established exchanges and the need for market‑maker support may delay the ETF's traction.

Relevance 6/10Novelty 6/10Timing: today

Background

The article discusses Westwood Holdings Group's role in the Texas Stock Exchange launch and its new AI‑focused power infrastructure ETF.

Company-level read

Ticker impact

$WHGBullishHigh confidence
Context

Westwood Holdings Group announced the launch of its first ETF on the new Texas Stock Exchange, marking the firm's entry into a Texas‑based exchange platform.

Expected impact

likely upward pressure as investors price in the new product and potential fee revenue

Evidence & confidence

First‑time ETF launch on a novel exchange is a material corporate development for a listed asset manager.

Market effects

May spur other asset managers to consider Texas‑based listings, expanding the regional ETF market.

Highlights Dallas as an emerging financial hub, potentially attracting more capital to Texas exchanges.

Shows diversification of exchange venues beyond traditional NY/NASDAQ hubs, relevant for global investors tracking market infrastructure trends.

Counterpoint

The Texas Stock Exchange lacks liquidity and regulatory depth, which could limit the ETF's success and weigh on Westwood's stock.

Key entities

  • Westwood Holdings Group

    Dallas‑based asset manager listed on NYSE (ticker WHG) launching an ETF on TXSE.

  • Texas Stock Exchange (TXSE)

    Newly launched exchange backed by major institutional investors.

Related articles

$WHGMed

Westwood Holdings (WHG) Q2 2026 Earnings Call Transcript

Westwood Holdings Group (WHG) reported Q2 2026 revenues of $25.3 million and net income of $1.5 million, or $0.17 per diluted share. Economic earnings were $3.0 million, or $0.33 per share. Assets under management were $17.0 billion after $1.6 billion net outflows. The firm said its ETF, private capital, and managed solutions segments each exceed $500 million and noted the PWRX ETF will list mid-September on the Texas Stock Exchange.

$WHGMed

Westwood Holdings Group, Inc. Reports Second Quarter 2026 Results

WESTWOOD HOLDINGS GROUP INC (WHG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Westwood Holdings Group, Inc. Reports Second Quarter 2026 Results Private Capital platform surpassed $500 million in assets Managed Investment Solutions flows reached $350 million Dallas, TX, August 6, 2026 – Westwood Holdings Group, Inc. (NYSE: WHG) today reported second quarter

$CMPXMedAI 8/10

Compass Therapeutics publishes tovecimig trial results in JCO

Compass Therapeutics (NASDAQ:CMPX) published Phase 2/3 trial results for tovecimig in the Journal of Clinical Oncology. The study met primary and secondary endpoints, showing improved response rates and progression-free survival in advanced biliary tract cancer patients compared to paclitaxel alone. However, overall survival showed no significant difference, and adverse events were higher in the combination arm. Tovecimig remains investigational.